Defective recombinant adenoviruses expressing cytokines for antitumor treatment
AssigneesCentre National De La Recherche Scientifique, Institut Gustave Roussy
InventorsHedi Mohamed Haddada, Thierry Ragot, Michel Perricaudet
Life of this patent
Estimating the term…
Abstract
A recombinant nucleic acid used for the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. This recombinant adenovirus is useful in the preparation of anti-tumoral drugs which can be directly injected into the tumor of the host.
Claims1
A method for treating a tumor in patients in need of such treatment, said method comprising injecting an effective amount of a pharmaceutical composition into said tumor wherein said pharmaceutical composition comprises:
- (a) a replication-defective adenoviral vector lacking the E1A, E2B and E3 regions of an adenovirus;
- and comprising a nucleic acid sequence coding for a cytokine, under the control of an adenovirus late promoter, and wherein said cytokine is interleukin-2;
- and
- (b) a pharmaceutically acceptable vehicle, wherein said pharmaceutical composition causes regression of said tumor in at least 40% to 50% of patients.
Dependencies are inferred from the claim text.